These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29206214)

  • 1. Immunotherapy for Prostate Cancer: Where We Are Headed.
    Schepisi G; Farolfi A; Conteduca V; Martignano F; De Lisi D; Ravaglia G; Rossi L; Menna C; Bellia SR; Barone D; Gunelli R; De Giorgi U
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
    Comiskey MC; Dallos MC; Drake CG
    Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives in prostate cancer vaccines.
    Arlen PM; Gulley JL
    Anticancer Agents Med Chem; 2009 Dec; 9(10):1052-7. PubMed ID: 19719454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
    Patel D; McKay R; Parsons JK
    Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the spectrum of immune checkpoints in prostate cancer.
    Sena LA; Denmeade SR; Antonarakis ES
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1253-1266. PubMed ID: 34263692
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From bench to bedside: immunotherapy for prostate cancer.
    Tse BW; Jovanovic L; Nelson CC; de Souza P; Power CA; Russell PJ
    Biomed Res Int; 2014; 2014():981434. PubMed ID: 25276838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
    Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
    Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
    Dong B; Minze LJ; Xue W; Chen W
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in the management of prostate cancer.
    Slovin SF
    Oncology (Williston Park); 2007 Mar; 21(3):326-33; discussion 334, 338, 346-8. PubMed ID: 17447437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic vaccines for prevention of prostate cancer.
    Naz RK; Shiley B
    Front Biosci (Schol Ed); 2012 Jan; 4(3):932-40. PubMed ID: 22202100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising novel immunotherapies and combinations for prostate cancer.
    Arlen PM; Mohebtash M; Madan RA; Gulley JL
    Future Oncol; 2009 Mar; 5(2):187-96. PubMed ID: 19284377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic vaccines for prostate cancer.
    Tarassoff CP; Arlen PM; Gulley JL
    Oncologist; 2006 May; 11(5):451-62. PubMed ID: 16720845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.